namuscla
lupin europe gmbh - mexiletine hydrochloride - myotonic häired - südame teraapia - namuscla on näidustatud sümptomaatiline ravi myotonia täiskasvanud patsientidel, kellel on mitte-huumustoiteline myotonic häired.
onpattro
alnylam netherlands b.v. - patisiran naatrium - amüloidoos, perekondlik - muud närvisüsteemi ravimid - onpattro on näidustatud ravi päriliku transthyretin-vahendatud amüloidoos (hattr amüloidoos) täiskasvanud patsientidel, kellel on stage 1 ja stage 2 polüneuropaatia.
rameam kõvakapsel
krka d.d. novo mesto - ramipriil+amlodipiin - kõvakapsel - 5mg+5mg 90tk; 5mg+5mg 100tk; 5mg+5mg 60tk; 5mg+5mg 50tk; 5mg+5mg 30tk
ipratropium bromide newline pharma inhalatsiooniaerosool, lahus
newline pharma s.l.u. - ipratroopiumbromiid - inhalatsiooniaerosool, lahus - 20mcg 1annus 200annus 3tk; 20mcg 1annus 200annus 1tk
rameam kõvakapsel
krka d.d. novo mesto - ramipriil+amlodipiin - kõvakapsel - 5mg+10mg 60tk; 5mg+10mg 90tk; 5mg+10mg 30tk; 5mg+10mg 50tk
rameam kõvakapsel
krka d.d. novo mesto - ramipriil+amlodipiin - kõvakapsel - 10mg+5mg 100tk; 10mg+5mg 50tk; 10mg+5mg 30tk; 10mg+5mg 60tk
rameam kõvakapsel
krka d.d. novo mesto - ramipriil+amlodipiin - kõvakapsel - 10mg+10mg 100tk; 10mg+10mg 90tk; 10mg+10mg 60tk; 10mg+10mg 30tk; 10mg+10mg 50tk
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - immunosupressandid - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
ioa
n.v. organon - nomegestrol atsetaat, östradiooli - kontraceptsioon - suguhormoonid ja genitaalsüsteemi, - suukaudne kontratseptsioon.
nordimet
nordic group b.v. - metotreksaadi - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antineoplastilised ained - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.